Browsing Tag
antibody-drug conjugate
8 posts
Can immunotherapy finally replace chemo in bladder cancer? Keytruda–Padcev combo shows the way
Explore how Merck’s Keytruda and Padcev combo is redefining bladder cancer treatment without chemo. Survival gains, sector impact, and what’s next in focus.
Day One Biopharmaceuticals moves to acquire Mersana Therapeutics in $285m cancer-drug deal
Find out how Day One Biopharmaceuticals’ $285 million acquisition of Mersana Therapeutics could reshape the rare-cancer ADC landscape today.
FDA approves GSK’s Blenrep for myeloma—what sets it apart from CAR-T options?
GSK’s Blenrep approved by the FDA for relapsed multiple myeloma after Phase III trial success. Learn what this means for U.S. patients and global expansion.
Is this the most promising DLL3-targeting therapy yet? Zai Lab advances ADC into Phase 3
Zai Lab’s DLL3-targeting ADC for small cell lung cancer shows high brain metastasis activity; global Phase 3 trial now underway. Explore the data and future impact.
FDA clears Mabwell’s next-gen ADC 7MW4911: What’s at stake in the global GI oncology race?
Mabwell secures FDA IND for CDH17-targeting ADC 7MW4911, marking a major step in GI cancer therapy. Find out how this could reshape advanced oncology care.
Genentech’s Lunsumio and Polivy combination triples remission in relapsed large B-cell lymphoma
Genentech's chemo-free Lunsumio and Polivy combo tripled remission time in relapsed B-cell lymphoma, signaling a shift toward outpatient oncology treatment.
CStone advances CS5001 clinical trial for first-line DLBCL treatment in Australia
CStone Pharmaceuticals has taken a significant step in the development of its ROR1 antibody-drug conjugate with the submission…
Pfizer to acquire cancer-focused drugmaker Seagen in $43bn deal to expand oncology leadership
Pfizer is set to acquire Seagen for $43 billion in cash to boost its oncology drug pipeline and antibody-drug conjugate capabilities. Learn how the deal reshapes cancer therapeutics.